Daniel M. Scolnick is a registered patent attorney with Pepper Hamilton LLP, resident in the Berwyn office. He is a member of the firm's Health Sciences Department. A registered patent attorney since 2008, Dr. Scolnick concentrates his practice in intellectual property law, including strategic patent prosecution and counseling, developing product exclusivity strategies, due diligence, and transactional support for pharmaceutical, biotech, life sciences and chemical companies.
Dr. Scolnick’s clients include venture capital groups, academic institutions, start-up and mid-size biotechnology and pharmaceutical companies, and Fortune 500 companies, who are developing and marketing products in all areas of life sciences, including small molecules, peptides, biologics, diagnostics and devices.
As a Ph.D. candidate and a post-doctoral fellow at the University of Pennsylvania, Dr. Scolnick acquired extensive experience in biochemistry, protein chemistry and genetics. As an undergraduate, Dr. Scolnick’s research concentrated on organic chemistry where he focused on defining the structure and function of anticonvulsants by synthesizing various compounds and having them tested in an animal model. Dr. Scolnick’s experience also includes materials science work where he performed synthesis and analytical work at the University of Pennsylvania’s chemistry department as a summer fellow investigating the synthesis and purification techniques involving nanomaterials. Dr. Scolnick has also authored eight peer-reviewed scientific articles including one that was published in the journal Nature that described the cloning and characterization of a novel cell cycle gene that has been subsequently found to be intricately involved in the progression of many cancers.